Propanc Biopharma, Inc. has been told it might be removed from Nasdaq for not meeting price rules.

Oct 29, 2026, 5:51 PM ETTroubleRead the original at SEC EDGAR

Bad for PPCB

Propanc Biopharma received notice that its shares face Nasdaq removal for missing the $1 minimum share-price rule. It plans to appeal and says it believes it fixed the issue, but removal could make trading and fundraising harder.

PPCB · Propanc Biopharma, Inc.

AI read · Bad for PPCB

The AI's read

The notice does not change Propanc's daily operations or SEC filings. But an earlier reverse split means it gets no usual 180-day period to fix the share-price problem. Propanc plans to appeal and says it believes the share price now meets the rule. An appeal pauses removal, but it does not promise the panel will agree. Delisting could make shares harder to trade and fundraising harder.

Get alerts for PPCB

Follow Propanc Biopharma, Inc. (PPCB) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for PPCB

Free on the App Store and Google Play, or on the web.